Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera

Reikvam, Håkon; Tiu, Ramon V.

doi:10.1038/leu.2011.314

Cited by 55 publications

(46 citation statements)

References 123 publications

(128 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the JAK2V617F mutation is the most remarkable genetic mutation in MPN. The JAK2V617F mutation was first identified in patients with MPN in 2005 (Reikvam and Tiu, 2012;Bogani et al, 2013), and was proposed as a diagnostic criterion for BCR/ABL-negative MPN by the WHO in 2008. However, the pathogenesis of the JAK2V617F mutation in classic BCR/ABL-negative MPN remains unclear.…”

Section: Discussionmentioning

confidence: 99%

Correlative study between the JAK2V617F mutation and thrombosis in patients with myeloproliferative neoplasm

et al. 2016

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. In this study, we investigated the correlation between the JAK2V617F mutation and thrombosis in patients with myeloproliferative neoplasm (MPN) using real-time fluorescence quantitative PCR. The incidence of thrombus was monitored and blood and coagulation were routinely assayed in patients with MPN. The JAK2V617F mutation was found in 8/68 individuals in the control group (11.8%); it was expressed in 44/68 patients with MPN (64.7%), suggesting that the rate of this mutation was significantly higher in patients with MPN than that in the control group. Twenty-six MPN patients (38.2%) showed symptoms of thrombosis; MPN patients with thrombosis showed a significantly higher rate of the JAK2V617F mutation, were of a greater age, and had higher blood pressure than MPN patients without thrombosis. In addition, the white blood cells (WBC) (21.98 ± 1.95) and platelets (364.68 ± 97.72) were significantly higher in patients, expressing the mutated gene, with polycythemia vera than in the patients without the mutation. The WBC (32.89 ± 4.25) and hemoglobin (161.92 ± 16.19) were significantly increased in the essential thrombocythemia patients with gene mutation compared with the patients without mutation. MPN patients showed higher blood clotting ability than the control subjects; moreover, MPN patients with the JAK2V617F mutation showed higher blood clotting ability than those without the mutation. The findings of this study indicate that the JAK2V617F mutation is correlated with the incidence of thrombosis, and analysis of this mutation has important clinical significance in the diagnosis and treatment of MPN.

show abstract

Section: Discussionmentioning

confidence: 99%

Correlative study between the JAK2V617F mutation and thrombosis in patients with myeloproliferative neoplasm

et al. 2016

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…It has been estimated that thrombosis is present in 12%-39% of patients with polycythemia vera, 10%-29% with essential thrombocythemia and around 13% of myelofibrosis at the time of diagnosis [15][16][17]. Patients with myeloproliferative neoplasms are also at increased risk of recurrence: in a retrospective study in 235 polycythemia vera and 259 essential thrombocythemia patients, thrombosis recurred in 33.6% of cases, corresponding to 5.6% per year [58].…”

Section: Myeloproliferative Neoplasmsmentioning

confidence: 99%

“…However, the type of thrombosis (i.e., arterial or venous) greatly depends on age and gender, being abdominal venous thrombosis often a presenting feature of young women with myeloproliferative neoplasms [60]. Indeed, venous thromboses at unusual sites, such as cerebral sinus and splanchnic (i.e., BuddChiari syndrome and portal vein thrombosis) vessels have a high prevalence among patients with myeloproliferative neolplasms and not rarely are the presenting feature of the disease, leading ultimately to their diagnosis [16]. In a study of 139 patients with cerebral, portal, or mesenteric vein thrombosis, about 14% fulfilled criteria for having polycythemia vera or essential thrombocytemia at time of presentation, about 95% of which were JAK2V617F positive [61].…”

Section: Myeloproliferative Neoplasmsmentioning

confidence: 99%

Thromboembolic risk in hematological malignancies

Franchini

2015

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

There are a growing number of studies documenting that, similarly to patients with solid cancers, also patients with hematological malignancies (i.e., acute leukemia, lymphoproliferative and myeloproliferative neoplasms and plasma cell disorders) are at increased risk of thrombosis. The pathogenesis of the hypercoagulable state associated with hematological cancers is often multifactorial. Contributor factors include tumor cell-derived procoagulants, antineoplastic therapies, central venous catheters, concomitant infections and advanced age. In this narrative review, the epidemiology, pathogenesis and management of thrombosis in patients with hematological malignancies are reviewed.

show abstract

“…In contrast, the association of antiplatelet agents plus vitamin K antagonists resulted in a higher incidence of major bleeding (2.8% patient-years) [38]. Recent guidelines therefore recommend oral anticoagulation in venous thrombosis for 3-6 months in PV and essentiel thrombocythemia (ET) patients [39].…”

Section: Anticoagulationmentioning

confidence: 99%

“…These new agents do not require anticoagulation monitoring and they have limited food-and drug-drug interactions due to their minimal metabolism through the CYP450 system. Of special interest in the setting of PV is the fact that the bleeding complications seem to be lower compared with vitamin-K antagonist [39].…”

Section: New Oral Anticoagulantsmentioning

confidence: 99%

Polycythemia Vera and Acute Coronary Syndromes: Pathogenesis, Risk Factors and Treatment

Gouri¹

2013

J Hematol Thrombo Diseases

View full text Add to dashboard Cite

Polycythemia vera is a chronic myeloproliferative disorder marked by significant thrombotic complications. Myocardial infarction and heart failure is the most common cause of death. Mechanisms involved in the pathogenesis of these complications are not yet well elucidate; erythrocytosis and quantitative platelet abnormalities may play a major role in the development of thrombosis and ischemia. Age older than 60 years and prior history of thrombosis are the two main risk factors. Evidence for the prevention and treatment of specific cardiovascular complications in PV is too scarce. However, current evidence supports the use of hydroxyurea as the initial choice of cytoreductive agent in PV patients with acute coronary syndrome.

show abstract

Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera

Cited by 55 publications

References 123 publications

Correlative study between the JAK2V617F mutation and thrombosis in patients with myeloproliferative neoplasm

Correlative study between the JAK2V617F mutation and thrombosis in patients with myeloproliferative neoplasm

Thromboembolic risk in hematological malignancies

Polycythemia Vera and Acute Coronary Syndromes: Pathogenesis, Risk Factors and Treatment

Contact Info

Product

Resources

About